Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Watch India launch advanced military satellite on rocket's 1st flight since May 2025 failure - 2Underestimated Metropolitan Experience Urban communities On the planet
- 3Thousands of New York City nurses set to strike Monday if deal isn't reached with hospitals
- 4Why home maintenance deserves a spot in the annual health and budget plans
- 5Israel Police arrest twenty-one as anti-war protests grow despite broad support for Iran war
- Holiday travel: Best days to hit the road as 110 million Americans expected to drive over Christmas and New Year's
- The Most Compelling Innovation Developments Somewhat recently
- Instructions to Utilize the Towing Highlights of the Slam 1500 Productively.
- Enormous Credit And All that You Really want To Be aware
- Hamas urges Hezbollah to kidnap Israeli soldiers in wake of Knesset passing death penalty bill
- Here's what the Artemis 2 astronauts will be doing on each day of NASA's historic moon mission
- Why screening for the deadliest cancer in the U.S. misses most cases
- 7 Strange Devices to Make Your Party Stick Out!
- Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest
